Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Brainstorm Cell Therapeutics

DB:GHDN
Snowflake Description

Moderate growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GHDN
DB
$122M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
  • Brainstorm Cell Therapeutics has significant price volatility in the past 3 months.
GHDN Share Price and Events
7 Day Returns
-2.7%
DB:GHDN
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
11.8%
DB:GHDN
-13.2%
DE Biotechs
-20.9%
DE Market
GHDN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Brainstorm Cell Therapeutics (GHDN) -2.7% -36.4% 15.1% 11.8% - -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • GHDN outperformed the Biotechs industry which returned -13.2% over the past year.
  • GHDN outperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
GHDN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Brainstorm Cell Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Brainstorm Cell Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Brainstorm Cell Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Brainstorm Cell Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €4.26.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Brainstorm Cell Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Brainstorm Cell Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GHDN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.06
NasdaqCM:BCLI Share Price ** NasdaqCM (2020-04-03) in USD $4.65
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Brainstorm Cell Therapeutics.

DB:GHDN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BCLI Share Price ÷ EPS (both in USD)

= 4.65 ÷ -1.06

-4.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Brainstorm Cell Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Brainstorm Cell Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Brainstorm Cell Therapeutics's expected growth come at a high price?
Raw Data
DB:GHDN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.38x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
58.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Brainstorm Cell Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Brainstorm Cell Therapeutics's assets?
Raw Data
DB:GHDN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-0.53
NasdaqCM:BCLI Share Price * NasdaqCM (2020-04-03) in USD $4.65
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:GHDN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BCLI Share Price ÷ Book Value per Share (both in USD)

= 4.65 ÷ -0.53

-8.82x

* Primary Listing of Brainstorm Cell Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Brainstorm Cell Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Take a look at Brainstorm Cell Therapeutics's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Brainstorm Cell Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Brainstorm Cell Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Brainstorm Cell Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Brainstorm Cell Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Brainstorm Cell Therapeutics expected to grow at an attractive rate?
  • Brainstorm Cell Therapeutics's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Brainstorm Cell Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Brainstorm Cell Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:GHDN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GHDN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 58.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GHDN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GHDN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 436 118 1
2023-12-31 306 66 1
2022-12-31 116 10 2
2021-12-31 44 -22 2
2020-12-31 0 -28 2
2020-04-05
DB:GHDN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -11 -23
2019-09-30 -12 -21
2019-06-30 -15 -18
2019-03-31 -11 -17
2018-12-31 -12 -14
2018-09-30 -12 -8
2018-06-30 -1 -8
2018-03-31 -3 -5
2017-12-31 -2 -5
2017-09-30 -1 -6
2017-06-30 -5 -5
2017-03-31 -5 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Brainstorm Cell Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Brainstorm Cell Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GHDN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Brainstorm Cell Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GHDN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 4.49 4.49 4.49 1.00
2023-12-31 2.49 2.49 2.49 1.00
2022-12-31 0.35 0.59 0.10 2.00
2021-12-31 -0.74 -0.68 -0.80 2.00
2020-12-31 -1.05 -0.94 -1.16 2.00
2020-04-05
DB:GHDN Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.06
2019-09-30 -0.98
2019-06-30 -0.88
2019-03-31 -0.81
2018-12-31 -0.70
2018-09-30 -0.42
2018-06-30 -0.39
2018-03-31 -0.29
2017-12-31 -0.26
2017-09-30 -0.31
2017-06-30 -0.27
2017-03-31 -0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Brainstorm Cell Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Brainstorm Cell Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Brainstorm Cell Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Brainstorm Cell Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Brainstorm Cell Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Brainstorm Cell Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Brainstorm Cell Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Brainstorm Cell Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Brainstorm Cell Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Brainstorm Cell Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GHDN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -23.25 5.80 17.20
2019-09-30 -20.94 5.90 14.88
2019-06-30 -18.49 5.61 12.85
2019-03-31 -16.68 5.91 10.77
2018-12-31 -13.95 5.77 8.29
2018-09-30 -8.29 5.52 2.87
2018-06-30 -7.52 5.49 2.06
2018-03-31 -5.47 4.52 1.01
2017-12-31 -4.95 4.02 0.98
2017-09-30 -5.85 3.02 2.87
2017-06-30 -5.06 2.64 2.49
2017-03-31 -4.98 2.84 2.21
2016-12-31 -4.98 2.83 2.25
2016-09-30 -5.74 3.08 2.75
2016-06-30 -6.74 3.30 3.47
2016-03-31 -8.04 3.45 4.69
2015-12-31 -8.49 3.59 4.95
2015-09-30 -9.83 4.04 5.77
2015-06-30 -9.65 3.83 5.84
2015-03-31 -9.37 3.26 5.34
2014-12-31 -9.25 2.65 4.77
2014-09-30 -7.73 2.18 3.98
2014-06-30 -6.39 1.59 3.21
2014-03-31 -5.93 1.92 3.08
2013-12-31 -4.90 2.13 2.92
2013-09-30 -4.26 1.93 2.35
2013-06-30 -4.33 2.09 2.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Brainstorm Cell Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Brainstorm Cell Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Brainstorm Cell Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Brainstorm Cell Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Brainstorm Cell Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Brainstorm Cell Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Brainstorm Cell Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Brainstorm Cell Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Brainstorm Cell Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Brainstorm Cell Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Brainstorm Cell Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Brainstorm Cell Therapeutics Company Filings, last reported 3 months ago.

DB:GHDN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -12.22 0.00 0.57
2019-09-30 -6.78 0.00 2.13
2019-06-30 -4.52 0.00 2.70
2019-03-31 0.33 0.00 6.23
2018-12-31 5.02 0.00 7.06
2018-09-30 9.98 0.00 10.89
2018-06-30 12.87 0.00 17.44
2018-03-31 3.83 0.00 5.61
2017-12-31 5.88 0.00 7.76
2017-09-30 5.20 0.00 10.55
2017-06-30 7.29 0.00 6.72
2017-03-31 8.24 0.00 8.35
2016-12-31 9.90 0.00 9.99
2016-09-30 10.53 0.00 11.19
2016-06-30 11.87 0.00 11.48
2016-03-31 12.57 0.00 12.95
2015-12-31 14.13 0.00 15.96
2015-09-30 15.52 0.00 17.15
2015-06-30 17.84 0.00 19.70
2015-03-31 19.66 0.00 21.35
2014-12-31 6.68 0.00 8.54
2014-09-30 8.90 0.00 10.57
2014-06-30 10.60 0.00 11.33
2014-03-31 0.86 0.00 3.03
2013-12-31 2.74 0.00 3.50
2013-09-30 4.54 0.00 5.12
2013-06-30 2.36 0.00 2.54
  • Brainstorm Cell Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Brainstorm Cell Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Brainstorm Cell Therapeutics has less than a year of cash runway based on current free cash flow.
  • Brainstorm Cell Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.8% each year.
X
Financial health checks
We assess Brainstorm Cell Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Brainstorm Cell Therapeutics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Brainstorm Cell Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Brainstorm Cell Therapeutics dividends.
If you bought €2,000 of Brainstorm Cell Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Brainstorm Cell Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Brainstorm Cell Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GHDN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GHDN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Brainstorm Cell Therapeutics has not reported any payouts.
  • Unable to verify if Brainstorm Cell Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Brainstorm Cell Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Brainstorm Cell Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Brainstorm Cell Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Brainstorm Cell Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Brainstorm Cell Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Brainstorm Cell Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chaim Lebovits
COMPENSATION $1,056,276
AGE 48
TENURE AS CEO 4.6 years
CEO Bio

Mr. Chaim Lebovits has served as the Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since September 22, 2015 and had served as its President since July 3, 2007 until April 2020. Mr. Lebovits serves as the Chief Executive Officer and President at ACC International Holdings Ltd. He has been the President of Dominion Minerals Corp. since July 30, 2008. He is the Founder of Rialto Energy (Côte d'Ivoire) Limited (AKA C & L Natural Resources Limited). He has been at the forefront of investments into mining and natural resources in emerging markets, especially the African region, for a number of years. He is active in gold exploration activities in Africaand oil and gas exploration in Israel. He served as the Principal Executive Officer at Brainstorm Cell Therapeutics Inc. since August 1, 2013. Mr. Lebovits led and negotiated many successful transactions with and on behalf of various African governments and international mining businesses. He has been a Director of Dominion Minerals Corp., since July 30, 2008. He served as a Director of Shemen Oil and Gas Resources Ltd. Mr. Lebovits served as a Non-Executive Director of Azonto Petroleum Ltd (formerly, Rialto Energy Limited) from July 24, 2010 to April 5, 2012.

CEO Compensation
  • Chaim's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Chaim's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Brainstorm Cell Therapeutics management team in years:

1.8
Average Tenure
48
Average Age
  • The average tenure for the Brainstorm Cell Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Chaim Lebovits

TITLE
Chief Executive Officer
COMPENSATION
$1M
AGE
48
TENURE
4.6 yrs

Irit Arbel

TITLE
Founder & Vice Chair of the Board
COMPENSATION
$84K
AGE
59

Ralph Kern

TITLE
President & Chief Medical Officer
COMPENSATION
$852K
AGE
61

Preetam Shah

TITLE
Executive VP
COMPENSATION
$883K
AGE
46
TENURE
0.6 yrs

Uri Yablonka

TITLE
Executive VP
COMPENSATION
$44K
AGE
42
TENURE
3.1 yrs

David Setboun

TITLE
Executive VP & COO

Yael Gothelf

TITLE
Vice President of Scientific & Regulatory Affairs

Daniel Offen

TITLE
Chief Scientific Advisor

Arturo Araya

TITLE
Chief Commercial Officer
COMPENSATION
$20K
AGE
48
TENURE
1.6 yrs

Susan Ward

TITLE
Head of Clinical Operations
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Brainstorm Cell Therapeutics board of directors in years:

4.5
Average Tenure
66.5
Average Age
  • The tenure for the Brainstorm Cell Therapeutics board of directors is about average.
Board of Directors

Jacob Frenkel

TITLE
Chairman of the Board
AGE
76
TENURE
0.1 yrs

Irit Arbel

TITLE
Founder & Vice Chair of the Board
COMPENSATION
$84K
AGE
59
TENURE
0.1 yrs

Uri Yablonka

TITLE
Executive VP
COMPENSATION
$44K
AGE
42
TENURE
5.8 yrs

Malcolm Taub

TITLE
Independent Director
COMPENSATION
$47K
AGE
73
TENURE
11.1 yrs

Jerold Chun

TITLE
Chairman of Scientific Advisory Board
TENURE
2.1 yrs

Harvey Krueger

TITLE
Member of Business Advisory Board
AGE
89
TENURE
12.7 yrs

Rasheda Ali

TITLE
Member of Business Advisory Board
TENURE
12.5 yrs

Andy Card

TITLE
Member of Business Advisory Board
AGE
71
TENURE
9.1 yrs

June Almenoff

TITLE
Independent Director
COMPENSATION
$38K
AGE
62
TENURE
3.2 yrs

Tony Polverino

TITLE
Independent Director
COMPENSATION
$30K
AGE
56
TENURE
2.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
27. Dec 19 Buy Ralph Kern Individual 24. Dec 19 24. Dec 19 3,000 €3.50 €10,495
27. Dec 19 Buy Preetam Shah Individual 24. Dec 19 24. Dec 19 11,600 €3.57 €41,410
27. Dec 19 Buy Arturo Araya Individual 24. Dec 19 24. Dec 19 3,000 €3.52 €10,549
21. Nov 19 Sell Karina Daly Individual 30. Sep 19 17. Oct 19 -10,818 €3.57 €-38,040
21. Nov 19 Buy Essig Research, Inc. Company 14. Nov 19 18. Nov 19 12,565 €3.34 €41,842
21. Nov 19 Sell Joseph Daly Individual 18. Oct 19 24. Oct 19 -11,220 €3.53 €-39,489
21. Nov 19 Buy Joseph Daly Individual 29. Oct 19 15. Nov 19 449,401 €3.31 €1,473,519
X
Management checks
We assess Brainstorm Cell Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Brainstorm Cell Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient’s own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Details
Name: Brainstorm Cell Therapeutics Inc.
GHDN
Exchange: DB
Founded: 2000
$113,057,145
26,230,839
Website: http://www.brainstorm-cell.com
Address: Brainstorm Cell Therapeutics Inc.
1325 Avenue of Americas,
28th Floor,
New York,
New York, 10019,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BCLI Common Stock Nasdaq Capital Market US USD 14. May 2003
DB GHDN Common Stock Deutsche Boerse AG DE EUR 14. May 2003
Number of employees
Current staff
Staff numbers
32
Brainstorm Cell Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 20:32
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/02/20
Last earnings filing: 2020/02/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.